Mitochondrial enzyme ABAD and its role in the development and treatment of Alzheimer’s disease


Authors: Ondřej Benek;  Kamil Musílek;  Kamil Kuča
Published in: Čes. slov. Farm., 2012; 61, 144-149
Category: Review Articles

Došlo 15. května 2012 / Přijato 2. července 2012

Overview

The amyloid-ß peptide (Aß) has been associated with Alzheimer’s disease (AD) for some time. The original amyloid cascade hypothesis declared that the insoluble extracellular plaques were responsible for main Aß toxicity. Nowadays, this hypothesis is outdated and soluble intracellular Aß forms and their effects within the cell have come into the centre of attention. There are many intracellular proteins interacting with Aß including the mitochondrial enzyme amyloid-binding alcohol dehydrogenase (ABAD). The interaction between ABAD and Aß impairs mitochondrial functions and ultimately results in cell death. In this review, current findings concerning the enzyme ABAD are summarized. Its role in AD development and its interaction with Aß as a potential therapeutic target are discussed.

Keywords:
Alzheimer’s disease, amyloid-ß peptide, mitochondrial dysfunction, amyloid-binding alcohol dehydrogenase, frentizole


Sources

1. Price D. L., Sisodia S. S.:Mutant genes in familial Alzheimer’s disease and transgenic models. Annu. Rev. Neurosci. 1998; 21, 479–505.

2. Selkoe D. J. Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature. 1999; 399(Suppl), A23–31.

3. Reddy P. H., Mani G., Park B. S., et al. Differential loss of synaptic proteins in Alzheimer’s disease: implications for synaptic dysfunction. J. Alzheimers Dis. 2005; 7(2), 103–117; discussion 173–180.

4. Golde T. E. Inflammation takes on Alzheimer disease. Nat. Med. 2002; 8(9), 936–938.

5. Reddy P. H., McWeeney S., Park B. S. et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease. Hum. Mol. Genet. 2004; 13(12), 1225–1240.

6. Reddy P. H., Beal M. F. Are mitochondria critical in the pathogenesis of Alzheimer’s disease? Brain Res. Brain Res. Rev. 2005; 49(3), 618–632.

7. Reddy P. H., McWeeney S. Mapping cellular transcriptosomes in autopsied Alzheimer’s disease subjects and relevant animal models. Neurobiol. Aging. 2006; 27(8), 1060–1077.

8. Keller J. N. Age-related neuropathology, cognitive decline, and Alzheimer’s disease. Ageing Res. Rev. 2006; 5(1), 1–13.

9. Selkoe D. J. Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 2001; 81(2), 741–766.

10. Hardy J. A., Higgins G. A. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992; 256(5054), 184–185.

11. Dahlgren K. N., Manelli A. M., Stine W. B. Jr., Baker L. K., Krafft G. A., LaDu M. J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 2002; 277(35), 32046–32053.

12. Gouras G. K., Tsai J., Naslund J. et al. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000; 156(1), 15–20.

13. Wirths O., Multhaup G., Bayer T. A. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. J. Neurochem. 2004; 91(3), 513–520.

14. Tillement L., Lecanu L., Papadopoulos V. Alzheimer’s disease: effects of ß-amyloid on mitochondria. Mitochondrion. 2011; 11(1), 13–21.

15. Hirai K., Aliev G., Nunomura A. et al. Mitochondrial abnormalities in Alzheimer’s disease. J. Neurosci. 2001; 21(9), 3017–3023.

16. Bubber P., Haroutunian V., Fisch G., Blass J. P., Gibson G. E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol. 2005; 57(5), 695–703.

17. Butterfield D. A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide. Trends Mol Med. 2001; 7(12), 548–554.

18. LaFerla F. M. Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease. Nat. Rev. Neurosci. 2002; 3(11), 862–872.

19. Manczak M., Park B. S., Jung Y., Reddy P. H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med. 2004; 5(2), 147–162.

20. Fernández-Vizarra P., Fernández A. P., Castro-Blanco S. et al. Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer’s disease. Histol. Histopathol. 2004; 19(3), 823–844.

21. Lustbader J. W., Cirilli M., Lin C. et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science. 2004; 304(5669), 448–452.

22. Kim H. S., Lee J. H., Lee J. P. et al. Amyloid beta peptide induces cytochrome C release from isolated mitochondria. Neuroreport. 2002; 13(15), 1989–1993.

23. Aleardi A. M., Benard G., Augereau O. et al. Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J. Bioenerg. Biomembr. 2005; 37(4), 207–225.

24. Moreira P. I., Santos M. S., Moreno A., Rego A. C., Oliveira C. Effect of amyloid beta-peptide on permeability transition pore: a comparative study. J. Neurosci. Res. 2002; 69(2), 257–267.

25. Hansson Petersen C. A., Alikhani N., Behbahani H. et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. USA 2008; 105(35), 13145–13150.

26. Area-Gomez E., de Groof A. J. C., Boldogh I., et al. Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am. J. Pathol. 2009; 175(5), 1810–1816.

27. Muirhead K. E. A., Borger E., Aitken L., Conway S. J., Gunn-Moore F. J. The consequences of mitochondrial amyloid beta-peptide in Alzheimer’s disease. Biochem. J. 2010; 426(3), 255–270.

28. Yan S. D., Fu J., Soto C. et al. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer’s disease. Nature. 1997; 389(6652), 689–695.

29. Du H., Guo L., Fang F. et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat. Med. 2008; 14(10), 1097–1105.

30. Verdier Y., Földi I., Sergeant N. et al. Characterization of the interaction between Abeta 1-42 and glyceraldehyde phosphodehydrogenase. J. Pept. Sci. 2008; 14(6), 755–762.

31. Park H. J., Seong Y. M., Choi J. Y., Kang S., Rhim H. Alzheimer’s disease-associated amyloid beta interacts with the human serine protease HtrA2/Omi. Neurosci. Lett. 2004; 357(1), 63–67.

32. He X. Y., Schulz H., Yang S. Y. A human brain L-3-hydroxyacyl-coenzyme A dehydrogenase is identical to an amyloid beta-peptide-binding protein involved in Alzheimer’s disease. J. Biol. Chem. 1998; 273(17), 10741–10746.

33. He X. Y., Merz G., Yang Y. Z., Mehta P., Schulz H., Yang S. Y. Characterization and localization of human type10 17beta-hydroxysteroid dehydrogenase. Eur. J. Biochem. 2001; 268(18), 4899–4907.

34. He X. Y., Yang Y. Z., Schulz H., Yang S. Y. Intrinsic alcohol dehydrogenase and hydroxysteroid dehydrogenase activities of human mitochondrial short-chain L-3-hydroxyacyl-CoA dehydrogenase. Biochem. J. 2000; 345(Pt 1), 139–143.

35. Furuta S., Kobayashi A., Miyazawa S., Hashimoto T. Cloning and expression of cDNA for a newly identified isozyme of bovine liver 3-hydroxyacyl-CoA dehydrogenase and its import into mitochondria. Biochim. Biophys. Acta. 1997; 1350(3), 317–324.

36. He X. Y., Wen G. Y., Merz G. et al. Abundant type 10 17 beta-hydroxysteroid dehydrogenase in the hippocampus of mouse Alzheimer’s disease model. Brain Res. Mol. Brain Res. 2002; 99(1), 46–53.

37. Ofman R., Ruiter J. P. N., Feenstra M. et al. 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency is caused by mutations in the HADH2 gene. Am. J. Hum. Genet. 2003; 72(5), 1300–1307.

38. He X. Y., Merz G., Mehta P., Schulz H., Yang S. Y. Human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase is a single-domain multifunctional enzyme. Characterization of a novel 17beta-hydroxysteroid dehydrogenase. J. Biol. Chem. 1999; 274(21), 15014–15019.

39. Powell A. J., Read J. A., Banfield M. J. et al. Recognition of structurally diverse substrates by type II 3-hydroxyacyl-CoA dehydrogenase (HADH II)/amyloid-beta binding alcohol dehydrogenase (ABAD). J. Mol. Biol. 2000; 303(2), 311–327.

40. Du Yan S., Zhu Y., Stern E. D. et al. Amyloid beta-peptide-binding alcohol dehydrogenase is a component of the cellular response to nutritional stress. J. Biol. Chem. 2000; 275(35), 27100–27109.

41. He X. Y., Wegiel J., Yang Y. Z., Pullarkat R., Schulz H., Yang S. Y. Type 10 17beta-hydroxysteroid dehydrogenase catalyzing the oxidation of steroid modulators of gamma-aminobutyric acid type A receptors. Mol. Cell. Endocrinol. 2005; 229(1–2), 111–117.

42. Holzmann J., Frank P., Löffler E., Bennett K. L., Gerner C., Rossmanith W. RNase P without RNA: identification and functional reconstitution of the human mitochondrial tRNA processing enzyme. Cell. 2008; 135(3), 462–474.

43. Yang S. Y., He X. Y., Miller D. Hydroxysteroid (17ß) dehydrogenase X in human health and disease. Mol. Cell. Endocrinol. 2011; 343(1–2), 1–6.

44. Kissinger C. R., Rejto P. A., Pelletier L. A. et al. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer’s disease therapeutics. J. Mol. Biol. 2004; 342(3), 943–952.

45. Xie Y., Deng S., Chen Z., Yan S., Landry D. W. Identification of small-molecule inhibitors of the Abeta-ABAD interaction. Bioorg. Med. Chem. Lett. 2006; 16(17), 4657–4660.

46. Yan Y., Liu Y., Sorci M. et al. Surface plasmon resonance and nuclear magnetic resonance studies of ABAD-Abeta interaction. Biochemistry. 2007; 46(7), 1724–1731.

47. Yan S. D., Shi Y., Zhu A. et al. Role of ERAB/L-3-hydroxyacyl-coenzyme A dehydrogenase type II activity in Abeta-induced cytotoxicity. J. Biol. Chem. 1999; 274(4), 2145–2156.

48. Oppermann U. C., Salim S., Tjernberg L. O., Terenius L., Jörnvall H. Binding of amyloid beta-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): regulation of an SDR enzyme activity with implications for apoptosis in Alzheimer’s disease. FEBS Lett. 1999; 451(3), 238–242.

49. Yao J., Taylor M., Davey F. et al. Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer’s disease patients and a transgenic Alzheimer’s disease mouse model. Mol. Cell. Neurosci. 2007; 35(2), 377–382.

50. Ren Y., Xu H. W., Davey F. et al. Endophilin I expression is increased in the brains of Alzheimer disease patients. J. Biol. Chem. 2008; 283(9), 5685–5691.

51. Ramjaun A. R., Angers A., Legendre-Guillemin V., Tong X. K., McPherson P. S. Endophilin regulates JNK activation through its interaction with the germinal center kinase-like kinase. J. Biol. Chem. 2001; 276(31), 28913–28919.

52. Sayre L. M., Zelasko D. A., Harris P. L., Perry G., Salomon R. G., Smith M. A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer’s disease. J. Neurochem. 1997; 68(5), 2092–2097.

53. Murakami Y., Ohsawa I., Kasahara T., Ohta S. Cytoprotective role of mitochondrial amyloid beta peptide-binding alcohol dehydrogenase against a cytotoxic aldehyde. Neurobiol. Aging. 2009; 30(2), 325–329.

54. Dye R. V., Miller K. J., Singer E. J., Levine A. J. Hormone replacement therapy and risk for neurodegenerative diseases. Int. J. Alzheimers Dis. 2012; 2012, 258454.

55. Yao J., Du H., Yan S. et al. Inhibition of Amyloid-beta (A beta) peptide-binding alcohol dehydrogenase-A beta interaction reduces a beta accumulation and improves mitochondrial function in a mouse model of Alzheimer’s disease. J. Neurosci. 2011; 31(6), 2313–2320.

56. Lim Y. A., Grimm A., Giese M. et al. Inhibition of the mitochondrial enzyme ABAD restores the amyloid-ß-mediated deregulation of estradiol. PLoS ONE. 2011; 6(12), e28887.

Labels
Pharmacy Clinical pharmacology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account